DK1991564T3 - Virosomlignende vesikler omfattende gp41-afledte antigener - Google Patents
Virosomlignende vesikler omfattende gp41-afledte antigenerInfo
- Publication number
- DK1991564T3 DK1991564T3 DK07733909.1T DK07733909T DK1991564T3 DK 1991564 T3 DK1991564 T3 DK 1991564T3 DK 07733909 T DK07733909 T DK 07733909T DK 1991564 T3 DK1991564 T3 DK 1991564T3
- Authority
- DK
- Denmark
- Prior art keywords
- virosome
- vesicles
- derived antigens
- antigens
- derived
- Prior art date
Links
- 101800001690 Transmembrane protein gp41 Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/000466 WO2007099387A1 (en) | 2006-03-03 | 2006-03-03 | Virosome-like vesicles comprising gp41-derived antigens |
| PCT/IB2007/000502 WO2007099446A2 (en) | 2006-03-03 | 2007-03-02 | Virosome-like vesicles comprising gp41-derived antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1991564T3 true DK1991564T3 (da) | 2013-12-16 |
Family
ID=37027640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07733909.1T DK1991564T3 (da) | 2006-03-03 | 2007-03-02 | Virosomlignende vesikler omfattende gp41-afledte antigener |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9216156B2 (da) |
| EP (1) | EP1991564B1 (da) |
| CN (1) | CN101437841B (da) |
| AP (1) | AP2008004615A0 (da) |
| BR (1) | BRPI0708519B8 (da) |
| CA (1) | CA2644282C (da) |
| DK (1) | DK1991564T3 (da) |
| EA (1) | EA018084B1 (da) |
| ES (1) | ES2437585T3 (da) |
| PL (1) | PL1991564T3 (da) |
| PT (1) | PT1991564E (da) |
| WO (2) | WO2007099387A1 (da) |
| ZA (1) | ZA200807592B (da) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1680446B1 (en) * | 2003-11-05 | 2007-10-31 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| ES2375995T3 (es) | 2004-09-17 | 2012-03-08 | University Of Massachusetts | Composiciones y sus usos para deficiencias de enzima lisosomal. |
| EP2222283A2 (en) | 2007-10-29 | 2010-09-01 | University of Massachusetts | Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna) |
| AU2009240772B2 (en) * | 2008-04-21 | 2015-04-30 | Marine Biotechnology Australia Pty Limited | Anti-viral nutraceutical |
| US8765137B2 (en) | 2009-02-06 | 2014-07-01 | Mymetics Corporation | Gp41 antigens |
| WO2010089402A1 (en) | 2009-02-06 | 2010-08-12 | Mymetics Corporation | Splitting gp41 |
| WO2011128720A1 (en) | 2010-04-14 | 2011-10-20 | Mymetics Corporation | Trans-activator of transcription protein |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 赤血球結合療法 |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2603241A2 (en) * | 2010-08-11 | 2013-06-19 | Jv Bio Srl | Multimeric inhibitors of viral fusion and uses thereof |
| WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| EP3016679B1 (en) * | 2013-07-02 | 2019-03-27 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| KR20240154672A (ko) | 2014-02-21 | 2024-10-25 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| CN107073105B (zh) | 2014-09-12 | 2021-04-06 | 巴斯特威尔控股有限公司 | 用于提供含佐剂病毒体的方法及由此可获得的含佐剂病毒体 |
| WO2017044940A1 (en) * | 2015-09-10 | 2017-03-16 | Washington State University | Cell membrane-formed nanoscale vesicles and methods of using thereof |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| ES3052812T3 (en) | 2017-05-08 | 2026-01-14 | Flagship Pioneering Innovations V Inc | Compositions for facilitating membrane fusion and uses thereof |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| CN107462534B (zh) * | 2017-08-15 | 2019-11-29 | 吉林师范大学 | 一种检测生物巯基化合物的体系及其检测方法 |
| SG11202007606QA (en) | 2018-02-17 | 2020-09-29 | Flagship Pioneering Innovations V Inc | Compositions and methods for membrane protein delivery |
| SG11202011078VA (en) | 2018-05-09 | 2020-12-30 | Univ Chicago | Compositions and methods concerning immune tolerance |
| MX2020012295A (es) | 2018-05-15 | 2021-03-31 | Flagship Pioneering Innovations V Inc | Composiciones de fusosoma y usos de estas. |
| WO2020014209A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020102485A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| CA3120082A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| AU2019378036B2 (en) | 2018-11-14 | 2026-05-07 | Flagship Pioneering Innovations V, Inc | Compositions and methods for compartment-specific cargo delivery |
| US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
| WO2020121062A1 (en) | 2018-12-12 | 2020-06-18 | Anergis S.A. | Methods of improving efficacy of allergy vaccines |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| CN111560352B (zh) * | 2020-06-02 | 2023-03-24 | 新疆农业大学 | 一种病毒样囊泡及其制备方法和应用 |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| US20250230511A1 (en) | 2021-10-29 | 2025-07-17 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| CA3239381A1 (en) | 2021-12-03 | 2023-06-08 | David R. Liu | Compositions and methods for efficient in vivo delivery |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN120303407A (zh) | 2022-05-17 | 2025-07-11 | 恩维洛普治疗有限责任公司 | 用于有效体内递送的组合物和方法 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| CN117024549B (zh) * | 2023-08-04 | 2024-11-26 | 重庆市畜牧科学院 | 一种含d型非天然氨基酸的蜂毒肽衍生物及其制备方法与应用 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU655823B2 (en) | 1991-05-08 | 1995-01-12 | Crucell Switzerland Ag | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| FR2771011B1 (fr) * | 1997-11-17 | 2000-01-28 | Hippocampe | Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale |
| AU2003253874A1 (en) | 2002-07-15 | 2004-02-02 | Aviza Technology, Inc. | Method and apparatus for supporting semiconductor wafers |
| PL377161A1 (pl) | 2002-11-21 | 2006-01-23 | Pevion Biotech Ltd. | Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki |
| US7198791B2 (en) * | 2003-03-03 | 2007-04-03 | Pluschke, Gerd Et Al. | Compositions and methods for the generation of protective immune responses against malaria |
| RU2390525C2 (ru) | 2003-07-30 | 2010-05-27 | Майметикс Корпорейшн | Новая растворимая и стабилизированная тримерная форма полипептидов gp41 |
| EP1680446B1 (en) | 2003-11-05 | 2007-10-31 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| US8147840B2 (en) * | 2004-05-14 | 2012-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid |
-
2006
- 2006-03-03 WO PCT/IB2006/000466 patent/WO2007099387A1/en not_active Ceased
-
2007
- 2007-03-02 EP EP07733909.1A patent/EP1991564B1/en active Active
- 2007-03-02 US US12/281,256 patent/US9216156B2/en active Active
- 2007-03-02 ZA ZA200807592A patent/ZA200807592B/xx unknown
- 2007-03-02 PL PL07733909T patent/PL1991564T3/pl unknown
- 2007-03-02 ES ES07733909.1T patent/ES2437585T3/es active Active
- 2007-03-02 AP AP2008004615A patent/AP2008004615A0/xx unknown
- 2007-03-02 EA EA200801798A patent/EA018084B1/ru not_active IP Right Cessation
- 2007-03-02 PT PT77339091T patent/PT1991564E/pt unknown
- 2007-03-02 WO PCT/IB2007/000502 patent/WO2007099446A2/en not_active Ceased
- 2007-03-02 CN CN2007800159618A patent/CN101437841B/zh not_active Expired - Fee Related
- 2007-03-02 DK DK07733909.1T patent/DK1991564T3/da active
- 2007-03-02 CA CA2644282A patent/CA2644282C/en active Active
- 2007-03-02 BR BRPI0708519A patent/BRPI0708519B8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101437841B (zh) | 2013-07-24 |
| WO2007099446A2 (en) | 2007-09-07 |
| BRPI0708519A2 (pt) | 2011-05-31 |
| EP1991564B1 (en) | 2013-09-11 |
| ZA200807592B (en) | 2009-12-30 |
| US9216156B2 (en) | 2015-12-22 |
| PL1991564T3 (pl) | 2014-04-30 |
| EP1991564A2 (en) | 2008-11-19 |
| BRPI0708519A8 (pt) | 2019-01-08 |
| AP2008004615A0 (en) | 2008-10-31 |
| US20090202622A1 (en) | 2009-08-13 |
| EA200801798A1 (ru) | 2009-06-30 |
| WO2007099387A1 (en) | 2007-09-07 |
| CN101437841A (zh) | 2009-05-20 |
| CA2644282C (en) | 2017-06-13 |
| BRPI0708519B1 (pt) | 2019-04-16 |
| ES2437585T3 (es) | 2014-01-13 |
| EA018084B1 (ru) | 2013-05-30 |
| PT1991564E (pt) | 2013-11-25 |
| BRPI0708519B8 (pt) | 2021-05-25 |
| CA2644282A1 (en) | 2007-09-07 |
| WO2007099446A3 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2021027I1 (el) | Σκευασματα αντισωματων anti-cd20 | |
| ZA200807592B (en) | Virosome-like vesicles comprising gp41-derived antigens | |
| ATE450271T1 (de) | Impfstoff | |
| DK2068886T3 (da) | Lipidholdige præparater | |
| DK2234600T3 (da) | Antistofformulering | |
| ES1065656Y (es) | Helicoptero | |
| EP2025266A4 (en) | CUSHION DEVICE | |
| CR10571A (es) | Vacuna virica recombinante | |
| DK2051606T3 (da) | Lænestol | |
| EP2019779A4 (en) | HOT-SEALANT GAS GENERATOR | |
| EP2039418A4 (en) | Mixing apparatus | |
| DE502006006067D1 (de) | Ng | |
| EP2015785A4 (en) | AGRM2 ANTIGEN | |
| DE602007008903D1 (de) | Auspuffrohrstruktur | |
| DE602007001051D1 (de) | Projektor | |
| FI20065612L (fi) | Sivurajoitin | |
| DE602007000612D1 (de) | Projektor | |
| ES1062366Y (es) | Interruptor-seccionador aereo | |
| ITMN20060046A1 (it) | Aereo | |
| UA14268S (uk) | Респіратор | |
| UA12964S (uk) | Респіратор | |
| UA13753S (uk) | Респіратор | |
| ATE448843T1 (de) | Helikopter | |
| UA13744S (uk) | Каністра | |
| ITTO20060734A1 (it) | Elicottero |